‘‘(C) One infectious disease expert. 
‘‘(D) Five adults who are each— 
‘‘(i) a victim of a vaccine injury; or 
‘‘(ii) a parent of the victim of a vac-
cine-related injury. 
‘‘(E) One representative of the general 
public who— 
‘‘(i) is not the victim of a vaccine in-
jury; and 
‘‘(ii) does not have a conflict of inter-
est described in paragraph (1)(A), (1)(B), 
or (2) of section 2142(b). 
‘‘(F) One toxicologist. 
‘‘(G) One neurologist. 
‘‘(H) One geneticist. 
‘‘(I) One immunologist. 
‘‘(J) One State or local public health offi-
cer. 
‘‘(K) Not less than 4 and not more than 
6 additional representatives. 
‘‘(2) 
QUALIFICATIONS.—In 
appointing 
the 
members of the Commission, the Secretary shall en-
sure that not less than one-third of the members of 
the advisory council are selected from among indi-
viduals who have a vaccine-related injury or who 
VerDate Aug 31 2005 
00:24 Apr 21, 2007
Jkt 059200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H1973.IH
H1973
mstockstill on PROD1PC66 with BILLS
have an immediate family member with a vaccine-re-
lated injury (irrespective of whether there is a judi-
cial or administration finding of such injury). 
‘‘(3) CONFLICTS OF INTEREST.—In appointing 
the members of the Commission, the Secretary shall 
ensure that such members do not have any related 
financial conflict of interest. For purposes of this 
paragraph, the Secretary shall not treat as a conflict 
of interest the following: 
‘‘(A) In the case of a member appointed 
under paragraph (1)(A) who is employed in the 
vaccine manufacturing industry, the receipt of a 
salary or other benefits for such employment. 
‘‘(B) In the case of 2 of the members ap-
pointed under paragraph (1)(D), any pending 
claim for compensation for a vaccine-related in-
jury. 
‘‘SEC. 2146. FULL-TIME LIAISON. 
‘‘The Director for Vaccine Safety Evaluation shall 
designate an employee of the Agency to serve as a full- 
time liaison between the Agency and the Department of 
Defense, the National Institutes of Health, the Food and 
Drug Administration, and the Centers for Disease Control 
and Prevention, and any other agency as the Director de-
termines necessary. 
VerDate Aug 31 2005 
00:24 Apr 21, 2007
Jkt 059200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H1973.IH
H1973
mstockstill on PROD1PC66 with BILLS
‘‘SEC. 2147. DEFINITIONS. 
‘‘In this subtitle: 
‘‘(1) The term ‘advisory council’ means the ad-
visory council established pursuant to section 2145. 
‘‘(2) The term ‘Agency’ means the Agency for 
Vaccine Safety Evaluation. 
‘‘(3) The term ‘assets’ includes contracts, facili-
ties, property, records, unobligated or unexpended 
balances of appropriations, and other funds or re-
sources (other than personnel). 
‘‘(4) The term ‘functions’ includes authorities, 
powers, rights, privileges, immunities, programs, 
projects, activities, duties, and responsibilities. 
‘‘(5) The term ‘licensed vaccine’ means a vac-
cine with a biologics license in effect under section 
351 of the Public Health Service Act (42 U.S.C. 
262). 
‘‘(6) The term ‘personnel’ means officers and 
employees. 
‘‘(7) The term ‘Project’ means the Vaccine 
Safety Datalink Project. 
‘‘SEC. 2148. AUTHORIZATION OF APPROPRIATIONS. 
‘‘There is authorized to be appropriated— 
‘‘(1) for conducting and supporting research 
under this subtitle, $80,000,000 for fiscal year 
2008; and 
VerDate Aug 31 2005 
00:24 Apr 21, 2007
Jkt 059200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H1973.IH
H1973
mstockstill on PROD1PC66 with BILLS